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Industry	4.0	–	A	vision	also	for	personalised	medicine	supply	
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Abstract	Industry	4.0	foresees	a	digital	transformation	of	manufacturing	resulting	in	smart	factories	and	supply	chains.	At	the	heart	of	the	concept	lies	the	vision	of	interconnected	materials,	goods	and	machines,	where	goods	find	their	way	through	the	factory	and	the	supply	chain	to	the	customer	in	a	self-organised	manner.	Industry	4.0	is	gaining	traction	in	high	value	manufacturing	sectors.		This	perspective	paper	explores	what	this	technology-driven	vision	has	to	offer	for	the	biopharmaceutical	industry,	and	in	particular	cell	and	gene	therapies.	
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What	is	Industry	4.0?	Industry	4.0	envisages	factories	and	supply	chains	where	goods	and	machines	are	all	connected	to	the	internet,	communicating	with	each	other,	exchanging,	collecting	and	analysing	data,	and	coordinating	processes	in	a	distributed	fashion.	This	data-driven	integrated	system	will	enable	improved	responsiveness	in	manufacturing	leading	to	more	flexible	factories	of	the	future.		It	is	derived	from	several	strong	technological	trends:	First,	computer	chips,	sensors	and	transmitters	are	increasingly	miniaturized	and	become	ever	less	expensive,	which	allows	embedding	them	into	more	and	more	machines	and	also	goods.	Second,	wireless	communication	becomes	ubiquitous,	which	allows	connecting	almost	everything	to	the	internet,	blurring	the	boundary	between	the	digital	and	the	physical	world,	allowing	machines	and	products	to	communicate	directly	and	autonomously.	Together,	these	technologies	allow	for	the	creation	of	self-organising	systems	that	collect	and	exchange	data	on	an	unprecedented	scale,	and	make	decisions	autonomously,	intelligently	and	in	a	decentralised	fashion.	Add	to	this	mix	other	technological	advances	such	as	cloud	computing	which	offers	scalability	even	to	small	enterprises,	big	data	analytics	which	enables	the	handling	and	interpretation	of	massive	amounts	of	data	in	real	time,	and	artificial	intelligence	which	allows	machines	to	learn	and	adjust,	and	you	get	a	powerful	mix	that	is	able	to	transform	industry	processes	and	take	them	to	a	new	level.		Industry	4.0	started	as	a	German	initiative	[1],	and	its	name	was	chosen	because	its	promoters	see	it	as	the	fourth	industrial	revolution,	after	the	introduction	of	the	steam	engine,	mass	production,	and	electronics	and	IT	(robots	and	
		
programmable	logic	controllers).	But	the	topic	is	gaining	momentum	across	the	world,	and	similar	concepts	are	known	as	“Smart	Factory”,	“Advanced	Manufacturing”,	or,	not	limited	to	industrial	processes,	“Cyber-Physical	Systems”		[2]	and	the	“Internet	of	Things”	[3].	
	
	
What	Industry	4.0	promises	The	typical	and	most	prominent	scenario	of	Industry	4.0	is	the	self-organising	factory,	where	half-finished	goods	find	their	way	through	the	shop	floor	and	negotiate	their	processing	with	machines	autonomously.	This	scenario	resonates	very	well	with	the	manufacturing	industry,	because	it	promises	cheap	and	
efficient	mass	customization.	Yet,	the	vision	of	Industry	4.0	goes	far	beyond	this	example,	and	hopes	include:	- Real-time	control.	Aggregating	all	the	collected	information	centrally,	it	will	be	possible	to	generate	a	digital	real-time	image	of	the	entire	physical	production	process	in	the	control	centre.	Production	becomes	fully	transparent	and	thus	offers	more	opportunities	for	monitoring,	supervison,	control	and	optimisation,	even	across	locations.		- Integrated	maintenance.	Smart	production	lines	will	constantly	monitor	themselves,	and	can	alert	the	appropriate	personnel	quickly	if	any	problems	are	detected	or	anticipated,	or	even	resolve	many	problems	themselves.	Machines	may	be	able	to	predict	optimal	service	intervals	and	order	spare	parts	autonomously.	Technicians	will	be	able	to	monitor	and	interact	with	the	machines	remotely.	Together,	this	promises	to	reduce	machine	downtimes	and	the	cost	for	maintenance.	- Better	adaptability.	A	self-organizing	production	system	that	can	make	intelligent	decisions	in	a	decentralized	manner	is	much	more	flexible	and	responsive	than	centrally	controlled	production	systems.	This	promises	much	greater	adaptability	to	changing	demand	or	unforeseen	events	such	as	machine	breakdowns	or	contamination.	- Enhanced	collaboration	across	the	supply	chain.	With	goods	carrying	information	across	the	supply	chain,	and	a	more	integrated	approach	to	communication	and	end-to-end	information	exchange,	Industry	4.0	will	allow	a	much	better	coordination	of	the	entire	supply	chain.	- Better	track-and-trace	capabilities.	Industry	4.0	means	that	individual	goods	will	obtain	a	unique	identifier,	and	be	able	to	keep	track	of	all	the	information	related	to	their	individual	production	process.	This	will	allow	for	more	efficient	and	more	effective	quality	control,	and	help	quickly	identify	problems	in	the	production	process.	This	is	also	an	important	prerequisite	for	Quality	by	Design	(QbD)	processes.	- Smarter	products	and	new	business	models.	Connecting	goods	to	the	internet	will	not	only	help	in	coordinating	their	production,	but	also	allow	for	better	customer	services,	new	product	features	and	new	business	models.	This	includes	provision	of	“in-use”	information	on	the	product	back	to	the	manufacturer;	this	can	be	used	to	improve	product	and	process	design	for	future	products.		
Industry	4.0	in	the	Biopharmaceutical	Industry	
		
The	predominant	mode	of	operation	for	the	manufacture	of	biopharmaceuticals,	including	cell	and	gene	therapies,	is	batch	rather	than	continuous	processing	[e.g.	4-7].	This	makes	the	benefits	of	Industry	4.0	with	its	vision	of	a	self-organising	factory	less	obvious	for	the	biopharmaceutical	industry.	However,	the	biopharmaceutical	industry	is	currently	undergoing	a	shift	away	from	the	one-drug-fits-all	paradigm	towards	personalisation,	with	therapies	targeted	to	particular	groups	of	patients	(stratified)	or	individuals	(personalised)	such	as	the	case	of	patient-specific	autologous	cell	and	gene	therapies.	This	will	require	a	corresponding	shift	in	manufacturing	to	agile	small-scale	individualised	production	that	can	make-to-order	cost-effectively.	The	resulting	challenges	will	be	similar	to	the	mass	customisation	challenges	that	made	Industry	4.0	so	popular	in	other	manufacturing	industries	(e.g.	automotive),	heightened	by	the	regulatory	constraints	paramount	in	the	biopharmaceutical	industry	and	the	complex	biological	and	living	nature	of	the	materials	and	products.			But	when	looking	at	all	the	associated	benefits	of	Industry	4.0	mentioned	in	the	previous	section,	it	should	become	clear	that	this	paradigm	has	a	lot	more	to	offer	to	the	biopharmaceutical	industry.		Quality	trumps	cost	in	the	biopharmaceutical	sector.	Embracing	Industry	4.0	will	facilitate	the	biotech	sector’s	move	towards	QbD,	including	a	more	flexible	process	based	on	having	enhanced	product	and	process	understanding	that	can	be	used	to	adapt	the	process	to	manage	critical	sources	of	variability	[8,9].	This	is	because	Industry	4.0	will	connect	Process	Analytical	Technologies	(PAT)	comprised	of	sensors	with	multivariate	data	analytics	and	control	algorithms	as	well	as	electronic	data	records	and	enterprise	systems	to	enable	efficient	knowledge	sharing	across	components	in	the	supply	chain.				Such	a	knowledge-driven	Quality	by	Design	approach	will	provide	the	ability	to	control	variability	in	factors	such	as	raw	materials	and	donor	source	material,	which	are	particular	concerns	for	autologous	cell	therapies.	As	PAT	and	sensor	technologies	develop,	it	will	be	possible	to	develop	feedforward	control	algorithms	so	as	to	adjust	the	process	parameters	throughout	the	manufacturing	process	to	cope	with	feed	variability.	For	example,	for	autologous	cell	therapies	if	the	starting	cell	concentration	is	lower	than	expected	in	the	donor	source	material.	Industry	4.0	can	potentially	make	an	informed	decision	on	the	increase	in	culture	time	required	(within	validated	limits)	to	produce	the	required	final	number	of	cells	for	treatment.		Feedback	control,	for	example,	using	cell	characterisation	assays	and	associated	online	analytics	to	control	cell	culture	operation	will	also	be	desirable	in	future	so	as	to	consistently	achieve	desired	product	quality	attributes.	This	will	not	only	have	benefits	one	might	expect	such	as	reduced	wastage	and	improved	yields,	but	more	critically	for	patient-specific	cell	and	gene	therapies	this	could	be	the	difference	between	treating	a	life-threatening	disease	and	having	a	failed	patient	treatment;	it	may	not	be	possible	to	repeat	manufacturing	in	the	event	of	a	batch	failure,	especially	if	new	patient	source	material	is	required,	due	to	the	already	immune-compromised	health	of	the	patients.			
		
Furthermore,	the	trend	towards	more	patient-specific	therapies	will	result	in	an	explosion	in	quality	data,	batch	manufacturing	record	reviews	and	release	testing	required.	For	example,	QC/QA	functions	will	need	to	be	more	automated	with	continuous	real-time	release	methods	to	handle	larger	numbers	of	patients	per	year	so	as	to	avoid	becoming	a	bottleneck.	As	can	be	seen,	the	quality	infrastructure	will	lie	at	the	heart	of	the	digital	transformation	of	cell	and	gene	therapy	manufacture.		Enhanced	track-and-trace	capabilities	are	critical	for	cell	and	gene	therapies	and	in	particular	for	patient-specific	therapies	so	as	to	provide	assurance	that	the	patient’s’	treatment	is	from	their	own	starting	material.	In	such	a	setting,	the	supply	chain	changes	from	a	linear	to	a	circular	one	with	the	patient	or	donor	at	the	centre.			Furthermore,	autologous	immunotherapies	such	as	CAR	T-cells	require	careful	orchestration	of	three	main	manufacturing	pathways	(plasmid	DNA,	viral	vectors,	cells)	with	the	additional	challenge	of	different	centralised	versus	local	manufacturing	setups.	Whether	cell	therapies	(allogeneic	or	autologous)	are	shipped	fresh	or	cryopreserved,	both	require	temperature-controlled	conditions	with	real-time	temperature	reports.	Blood	banks	already	address	some	of	these	issues	with	barcoding	of	supplies	and	managing	the	logistics	of	handling	blood	products	requiring	controlled	temperature	storage	and	distribution.		However,	it	is	clear	that	innovative	solutions	from	Industry	4.0	will	provide	real-time	visibility	and	control	across	complex	cell	and	gene	therapy	supply	chains	from	material	sourcing	through	to	manufacturing	and	temperature-controlled	transport	to	patients.		This	is	particularly	critical	given	that	here	an	expensive	asset	($50k+)	needs	to	be	tracked	needle-to-needle	so	as	to	guarantee	chain	of	custody	and	ensure	timely	delivery	to	the	correct	patients.	This	needs	to	be	achieved	whilst	managing	temperature	and	time	risk,	co-ordinating	with	manufacturing	sites	for	capacity	sourcing	and	planning,	and	clinical	sites	manufacturing	,	as	well	as	factors	such	as	customs	challenges	when	shipping	[10].	It	is	encouraging	to	note	that	there	are	already	important	developments	in	track-and-trace	for	cell	therapies	and	these	are	more	advanced	than	elsewhere	in	the	biopharmaceutical	sector.		The	enhanced	track-and-trace	capabilities	of	Industry	4.0	will	also	make	it	easier	to	comply	with	different	geographical	regulatory	jurisdictions	that	may	have	differences	in	formulation,	packaging	or	quality	control	requirements.	Further	drivers	for	Industry	4.0	adoption	are	based	on	new	EU	regulation	that	is	likely	to	require	a	unique	serial	number	for	most	prescription	drugs	from	2018	[11],	as	well	as	WHO	estimates	that	about	10%	of	drugs	in	Europe	may	be	counterfeit	drugs	[12].	If	every	item	has	its	own	specific	identification	label,	it	is	straightforward	to	envision	a	system	where	every	patient	could	easily	check	the	origin	of	the	drug	they	have	been	given	by	simply	holding	its	packaging	in	front	of	their	computer’s	webcam.			Industry	4.0	will	also	help	in	the	biopharmaceutical	industry’s	transition	towards	increased	industrialisation.	In	some	cases	this	will	include	moving	from	batch	to	continuous	manufacturing.	Continuous	biomanufacturing	is	actively	
		
being	investigated	in	the	therapeutic	protein	manufacturing	space	with	a	potential	end-to-end	continuous	manufacturing	vision	[e.g.	13-15].	For	viral	vector	manufacture	for	cell	and	gene	therapies,	continuous	biomanufacture	is	being	explored	on	the	upstream	front,	with	perfusion	culture	in	fixed	bed	bioreactors	[16]	or	stirred	tank	bioreactors,	as	well	as	the	downstream	front	with	continuous	chromatography	[17].	For	cell	therapy	manufacture	one	can	also	envisage	the	use	of	perfusion	culture	to	enhance	productivities	within	a	smaller	footprint	linked	to	continuous	volume	reduction,	washing	[18]	and	purification,	where	appropriate.	For	continuous	biomanufacture,	the	sophisticated	monitoring	and	control	capabilities	expected	from	Industry	4.0	will	be	even	more	important	for	successful	implementation	and	track-and-trace.				Industry	4.0	will	support	also	the	formation	of	company	networks,	or	virtual	organizations,	by	enabling	more	efficient	communication	across	company	walls.	Given	the	general	trends	towards	specialisation	and	outsourcing	in	the	industry,	this	could	become	an	effective	coordination	mechanism.	Furthermore,	current	(bio)pharmaceutical	supply	chains	are	characterised	by	low	velocities	and	large	amounts	of	stocks	present	at	all	levels	in	the	supply	chain	[19];	the	adoption	of	Industry	4.0	should	lead	to	more	effective	material	management	and	improved	responsiveness.		Last	but	not	least,	Industry	4.0	will	enable	both	forward	flow	of	information	through	the	supply	chain	as	well	as	backward	flow	of	real-time	patient	data	with	direct	communication	between	manufacturer,	clinician,	payer	and	patient,	in	various	ways.	Monitoring	devices	worn	by	the	patient	would	allow	automatically	adjusting	the	treatment	(such	as	time	and	dosage)	to	a	patient’s	individual	lifestyle,	or	notify	a	doctor	if	it	detects	that	intervention	would	be	beneficial.	It	would	also	allow	a	much	better	monitoring	of	efficacy	and	detecting	side	effects	more	quickly.	A	pharmaceutical	pill	box	or	biopharmaceutical	self-administered	injection	(e.g.	sub-cutaneous	or	intramuscular)	linked	to	the	internet	could	send	the	patient	automatic	reminders	via	email	or	call	if	they	forget	to	take	their	medicine,	leading	to	better	patient	compliance.	It	could	also	automatically	re-order	medicine	as	needed,	which	would	be	immediately	known	to	the	manufacturer.	Such	approaches	not	only	promise	improved	delivery	of	the	drug,	but	also	lead	to	higher	customer	loyalty	and	retention.	With	many	more	possibilities	enabled	by	a	connected	patient,	and	radically	new	business	models,	this	clearly	has	the	potential	to	change	the	healthcare	industry	substantially.		
Challenges	As	exciting	as	the	vision	of	Industry	4.0	may	be,	there	are	still	numerous	challenges	that	need	to	be	addressed.	With	the	increased	interoperability	required	by	the	internet	of	things,	systems	need	to	be	able	to	communicate,	not	only	on	the	technical	level,	but	also	on	the	application	level.	This	means	global	standards	and	data	sharing	protocols	are	absolutely	crucial	for	its	success.			Obvious	concerns	when	connecting	everything	to	the	internet	are	safety	and	data	security.	Related	to	data	security	is	also	the	question	of	data	ownership.	Data	security	is	important	for	example	for	protection	of	intellectual	property	and	company	data,	but	is	of	particular	concern	to	the	(bio)pharmaceutical	industry	
		
because	health	data	is	very	sensitive.	And	an	increased	connectedness	also	comes	with	an	increased	risk	of	cyberattacks,	which	in	the	pharmaceutical	industry	could	for	example	lead	to	tampering	with	the	production	process	and	result	in	ineffective	or	even	harmful	manipulated	drugs	delivered	to	the	patient.	Even	without	a	maleficent	attacker,	one	has	to	think	about	liability	and	accountability	in	a	self-organized	production	network	consisting	of	multiple	parties	if	something	goes	wrong.	And	even	for	a	single	smart	machine,	one	can	ask	the	question	whether	it	is	the	drug	manufacturer’s	or	the	machine	manufacturer’s	responsibility	if	the	“intelligent”	machine	makes	incorrect	decisions.			Finally,	self-organising	systems	require	new	tools	and	paradigms	for	effective	control.	Since	these	systems	are	very	complex	and	rely	on	many	decentralized	decision	making	entities,	the	use	of	exact	and	provably	optimal	techniques	will	not	be	possible.	Instead,	those	systems	will	be	inherently	of	heuristic	nature	(e.g.,	[20])	and	the	regulatory	framework	which	currently	tightly	controls	every	step	in	the	biopharmaceutical	industry	would	have	to	become	much	more	open	to	allow	for	a	new	type	of	flexible	and	self-organized	production	processes.		
Translational	Insight	It	may	be	too	much	to	say	that	Industry	4.0	means	another	revolution	also	for	the	biopharmaceutical	industry.	But	the	technology	certainly	bears	great	potential,	in	particular	in	terms	of	fusion	of	automation	and	robotics	systems,	track-and-trace	capabilities,	real-time	quality	testing	and	control,	greater	collaboration	between	manufacturers	and	suppliers	and	end-to-end	communication.	This	will	enable	the	supply	chain	to	be	redesigned	and	customised	around	the	patient	and	to	bring	manufacturing	closer	to	patient	when	desired.	Industry	4.0	will	play	a	crucial	role	in	the	shift	to	personalised	medicine	and	enable	a	higher	level	of	mass	customisation	than	is	possible	today.		Implementation	will	require	disruptive	approaches	to	transform	the	supply	chain,	vendor-manufacturer	relationships	and	datasharing	protocols	to	increase	manufacturing	flexibility	whilst	allowing	for	cost-effective	production	of	small	lot	sizes.	In	order	to	take	full	advantage	of	Industry	4.0	the	cell	and	gene	therapy	sector	will	need	to	move	more	strongly	towards	digitally	integrated	and	automated	or	robotically-controlled	equipment	[e.g.	7,	21-22]	rather	than	the	manual,	labour-intensive	kit	in	use	today.	With	the	supply	chain	including	healthcare	providers	and	patient	data,	it	will	also	need	to	consider	challenges	around	data	ownership	and	the	implications	from	patient	feedback	data.	The	creation	of	automated	manufacturing	and	testing	solutions,	standardisation	of	procedures	across	the	supply	chain	as	well	as	real-time	traceability	has	the	potential	to	be	game-changing	and	a	critical	lever	for	survival	and	success	for	the	cell	and	gene	therapy	industry.	Industry	4.0	adoption	will	also	be	a	key	factor	in	ensuring	increased	patient	access	to	these	novel	biological	therapies	in	an	affordable	manner.		
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